Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency

M. Fanin, A. Anichini, D. Cassandrini, C. Fiorillo, S. Scapolan, C. Minetti, M. Cassanello, M. A. Donati, G. Siciliano, A. D'Amico, F. Lilliu, C. Bruno, C. Angelini

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

As genotype-phenotype correlations require the study of large patient populations, we investigated 49 Italian patients (33 unreported) with the muscle form of carnitine-palmitoyl-transferase-II (CPT-II) deficiency and CPT2 gene mutations. CPT enzyme activity below 25% of controls would lead to the development of muscle symptoms, and CPT activity below 15% would cause a relatively severe phenotype of the muscle form. Of the 15 different mutations found, 6 are novel (40%). A functional significance of mutations could be derived only for the two homozygous missense mutations found: both the p.S113L and the p.R631C (recurring in four unrelated patients from a genetic isolate) alleles caused a severe CPT enzyme defect (15% and 7%, respectively) and a relatively severe clinical phenotype of the muscle form. We identified three genotypes (homozygous p.R631C, homozygous p.S113L, and heterozygous null mutations) usually associated with a relatively severe and often life-threatening condition, which should be considered both in the clinical management of newly diagnosed patients (to prevent symptoms) and in their possible inclusion in therapeutic trials. We confirmed the existence of symptomatic heterozygous patient(s), through a family study, providing an important issue when offering genetic counseling and suggesting the crucial role of polymorphisms or environmental factors in determining the phenotype.

Original languageEnglish
Pages (from-to)232-239
Number of pages8
JournalClinical Genetics
Volume82
Issue number3
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Carnitine
Transferases
Muscles
Mutation
Phenotype
Muscle Development
Genetic Counseling
Genetic Association Studies
Missense Mutation
Enzymes
Alleles
Genotype
Population
Genes

Keywords

  • Carnitine-palmitoyl- transferase
  • CPT2
  • Genotype
  • Phenotype correlations
  • Symptomatic heterozygotes

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency. / Fanin, M.; Anichini, A.; Cassandrini, D.; Fiorillo, C.; Scapolan, S.; Minetti, C.; Cassanello, M.; Donati, M. A.; Siciliano, G.; D'Amico, A.; Lilliu, F.; Bruno, C.; Angelini, C.

In: Clinical Genetics, Vol. 82, No. 3, 09.2012, p. 232-239.

Research output: Contribution to journalArticle

Fanin, M. ; Anichini, A. ; Cassandrini, D. ; Fiorillo, C. ; Scapolan, S. ; Minetti, C. ; Cassanello, M. ; Donati, M. A. ; Siciliano, G. ; D'Amico, A. ; Lilliu, F. ; Bruno, C. ; Angelini, C. / Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency. In: Clinical Genetics. 2012 ; Vol. 82, No. 3. pp. 232-239.
@article{06d65f0db83f4ff09e5aa14e49ca57d0,
title = "Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency",
abstract = "As genotype-phenotype correlations require the study of large patient populations, we investigated 49 Italian patients (33 unreported) with the muscle form of carnitine-palmitoyl-transferase-II (CPT-II) deficiency and CPT2 gene mutations. CPT enzyme activity below 25{\%} of controls would lead to the development of muscle symptoms, and CPT activity below 15{\%} would cause a relatively severe phenotype of the muscle form. Of the 15 different mutations found, 6 are novel (40{\%}). A functional significance of mutations could be derived only for the two homozygous missense mutations found: both the p.S113L and the p.R631C (recurring in four unrelated patients from a genetic isolate) alleles caused a severe CPT enzyme defect (15{\%} and 7{\%}, respectively) and a relatively severe clinical phenotype of the muscle form. We identified three genotypes (homozygous p.R631C, homozygous p.S113L, and heterozygous null mutations) usually associated with a relatively severe and often life-threatening condition, which should be considered both in the clinical management of newly diagnosed patients (to prevent symptoms) and in their possible inclusion in therapeutic trials. We confirmed the existence of symptomatic heterozygous patient(s), through a family study, providing an important issue when offering genetic counseling and suggesting the crucial role of polymorphisms or environmental factors in determining the phenotype.",
keywords = "Carnitine-palmitoyl- transferase, CPT2, Genotype, Phenotype correlations, Symptomatic heterozygotes",
author = "M. Fanin and A. Anichini and D. Cassandrini and C. Fiorillo and S. Scapolan and C. Minetti and M. Cassanello and Donati, {M. A.} and G. Siciliano and A. D'Amico and F. Lilliu and C. Bruno and C. Angelini",
year = "2012",
month = "9",
doi = "10.1111/j.1399-0004.2011.01786.x",
language = "English",
volume = "82",
pages = "232--239",
journal = "Clinical Genetics",
issn = "0009-9163",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "3",

}

TY - JOUR

T1 - Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency

AU - Fanin, M.

AU - Anichini, A.

AU - Cassandrini, D.

AU - Fiorillo, C.

AU - Scapolan, S.

AU - Minetti, C.

AU - Cassanello, M.

AU - Donati, M. A.

AU - Siciliano, G.

AU - D'Amico, A.

AU - Lilliu, F.

AU - Bruno, C.

AU - Angelini, C.

PY - 2012/9

Y1 - 2012/9

N2 - As genotype-phenotype correlations require the study of large patient populations, we investigated 49 Italian patients (33 unreported) with the muscle form of carnitine-palmitoyl-transferase-II (CPT-II) deficiency and CPT2 gene mutations. CPT enzyme activity below 25% of controls would lead to the development of muscle symptoms, and CPT activity below 15% would cause a relatively severe phenotype of the muscle form. Of the 15 different mutations found, 6 are novel (40%). A functional significance of mutations could be derived only for the two homozygous missense mutations found: both the p.S113L and the p.R631C (recurring in four unrelated patients from a genetic isolate) alleles caused a severe CPT enzyme defect (15% and 7%, respectively) and a relatively severe clinical phenotype of the muscle form. We identified three genotypes (homozygous p.R631C, homozygous p.S113L, and heterozygous null mutations) usually associated with a relatively severe and often life-threatening condition, which should be considered both in the clinical management of newly diagnosed patients (to prevent symptoms) and in their possible inclusion in therapeutic trials. We confirmed the existence of symptomatic heterozygous patient(s), through a family study, providing an important issue when offering genetic counseling and suggesting the crucial role of polymorphisms or environmental factors in determining the phenotype.

AB - As genotype-phenotype correlations require the study of large patient populations, we investigated 49 Italian patients (33 unreported) with the muscle form of carnitine-palmitoyl-transferase-II (CPT-II) deficiency and CPT2 gene mutations. CPT enzyme activity below 25% of controls would lead to the development of muscle symptoms, and CPT activity below 15% would cause a relatively severe phenotype of the muscle form. Of the 15 different mutations found, 6 are novel (40%). A functional significance of mutations could be derived only for the two homozygous missense mutations found: both the p.S113L and the p.R631C (recurring in four unrelated patients from a genetic isolate) alleles caused a severe CPT enzyme defect (15% and 7%, respectively) and a relatively severe clinical phenotype of the muscle form. We identified three genotypes (homozygous p.R631C, homozygous p.S113L, and heterozygous null mutations) usually associated with a relatively severe and often life-threatening condition, which should be considered both in the clinical management of newly diagnosed patients (to prevent symptoms) and in their possible inclusion in therapeutic trials. We confirmed the existence of symptomatic heterozygous patient(s), through a family study, providing an important issue when offering genetic counseling and suggesting the crucial role of polymorphisms or environmental factors in determining the phenotype.

KW - Carnitine-palmitoyl- transferase

KW - CPT2

KW - Genotype

KW - Phenotype correlations

KW - Symptomatic heterozygotes

UR - http://www.scopus.com/inward/record.url?scp=84865073014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865073014&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0004.2011.01786.x

DO - 10.1111/j.1399-0004.2011.01786.x

M3 - Article

C2 - 21913903

AN - SCOPUS:84865073014

VL - 82

SP - 232

EP - 239

JO - Clinical Genetics

JF - Clinical Genetics

SN - 0009-9163

IS - 3

ER -